Search Results - M. Talpaz

  • Showing 1 - 10 results of 10
Refine Results
  1. 1

    P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE... by V. Gupta, J. Mascarenhas, M. Kremyanskaya, R. K. Rampal, M. Talpaz, J.-J. Kiladjian, A. Vannucchi, S. Verstovsek, G. Colak, D. Dey, C. Harrison

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  2. 2

    P1041: IMPACT OF FEDRATINIB ON SPLEEN VOLUME AND MYELOFIBROSIS SYMPTOMS IN PATIENTS WITH SUBSTANTIAL SPLENOMEGALY: POST HOC ANALYSES FROM THE JAKARTA AND JAKARTA2 TRIALS by J.-J. Kiladjian, A. Tefferi, F. Passamonti, A. Vannucchi, M. Talpaz, F. Cervantes, C. N. Harrison, R. A. Mesa, J. Mascarenhas, N. Schaap, S. Verstovsek, T. Devos, S. Rose, J. Zhang, O. Sy, A. Pardanani

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  3. 3

    P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREAT... by V. Gupta, A. Yacoub, S. Verstovsek, R. A. Mesa, C. N. Harrison, G. Barosi, J.-J. Kiladjian, H. J. Deeg, S. Fazal, L. Foltz, R. J. Mattison, C. B. Miller, V. Parameswaran, C. Hernandez, J. Zhang, M. Talpaz

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  4. 4

    S198: BET INHIBITOR PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS — JAK INHIBITOR-NAÏVE OR WITH SUBOPTIMAL RESPONSE TO RUXOLITINIB — PRELIMINARY DA... by J. Mascarenhas, M. Kremyanskaya, A. Patriarca, C. Harrison, P. Bose, R. K. Rampal, F Palandri, T. Devos, F. Passamonti, G. Hobbs, M. Talpaz, A. Vannucchi, J.-J. Kiladjian, S. Verstovsek, R. Hoffman, M. E. Salama, D. Chen, P. Taverna, A. Chang, G. Colak, S. Klein, V. Gupta

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  5. 5

    P707: DOSE MODIFICATION DYNAMICS OF PONATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) FROM THE PACE AND OPTIC TRIALS by J. Apperley, H. Kantarjian, M. Deininger, E. Abruzzese, J. Cortes, C. Chuah, D. J. DeAngelo, J. DiPersio, A. Hochhaus, J. Lipton, F. Nicolini, J. Pinilla-Ibarz, D. Rea, G. Rosti, P. Rousselot, M. Mauro, N. Shah, M. Talpaz, A. Vorog, X. Ren, E. Jabbour

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  6. 6

    P704: ASCIMINIB PROVIDES DURABLE MOLECULAR RESPONSES IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH THE T315I MUTATION: UPDATED EFFICACY AND SAFETY... by T. Hughes, J. E. Cortes, D. Réa, M. J. Mauro, A. Hochhaus, D.-W. Kim, K. Sasaki, F. Lang, M. C. Heinrich, M. Breccia, M. Deininger, Y.-T. Goh, J. J. Janssen, M. Talpaz, V. Gómez García de Soria, P. le Coutre, S. Kapoor, S. Cacciatore, F. Polydoros, N. Agrawal, F.-X. Mahon

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  7. 7

    B03 | PELABRESIB IN COMBINATION WITH RUXOLITINIB FOR JANUS KINASE INHIBITOR-NAIVE PATIENTS WITH MYELOFIBROSIS: 72-WEEK FOLLOW-UP WITH LONG-TERM EFFICACY OUTCOMES OF THE PHASE III M... by A. Vannucchi, R. Rampal, D. Chraniuk, S. Grosicki, E. Abruzzese, S. Lee, A. Lucchesi, A. Gerds, S. Oh, A. Patriarca, A. Álvarez Larrán, D. Lavie, V. Gupta, A. Kuykendall, P. Bose, M. Talpaz, F. Palandri, R. Mesa, J.J. Kiladjian, M. Wroclawska, M. Wu, A.M. Jegg, J. Mascarenhas, C. Harrison

    Published in Haematologica (2025-09-01)
    Get full text
    Article


  8. 8

    P1030: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF PELABRESIB (CPI-0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-NAÏVE MYEL... by C. Harrison, R. K. Rampal, V. Gupta, S. Verstovsek, M. Talpaz, J.-J. Kiladjian, R. Mesa, A. Kuykendall, A. Vannucchi, F. Palandri, S. Grosicki, T. Devos, E. Jourdan, M. J. Wondergem, H. K. Al-Ali, V. Buxhofer-Ausch, A. Alvarez-Larrán, S. Akhani, R. Muñoz-Carerras, Y. Sheykin, G. Colak, M. Harris, J. Mascarenhas

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  9. 9

    P1033: A PHASE 2 STUDY OF THE LSD1 INHIBITOR IMG-7289 (BOMEDEMSTAT) FOR THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA (ET) by F. Palandri, D. M. Ross, T. Cochrane, C. Tate, S. W. Lane, S. R. Larsen, A. T. Gerds, A. B. Halpern, J. Shortt, J. M. Rossetti, K. M. Pettit, J. Liang, A. Mead, M. Marchetti, A. Vannucchi, A. Wilson, J. R. Göthert, M. Hanna, A. Jones, J. Peppe, G. Natsoulis, T. McClure, W.-J. Hong, W. S. Stevenson, C. N. Harrison, M. Talpaz, N. Vianelli, H. Y. Rienhoff, Jr.

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  10. 10

    P1051: A PHASE 2 STUDY OF IMG-7289 (BOMEDEMSTAT) IN PATIENTS WITH ADVANCED MYELOFIBROSIS by H. Gill, A. Yacoub, K. Pettit, T. Bradley, A. Gerds, M. Tatarczuch, J. Shortt, N. Curtin, J. Rossetti, K. Burbury, A. Mead, J. Göthert, S. Koschmieder, A. Jones, J. Peppe, J. Dias, G. Natsoulis, T. McClure, M. Kleppe, W.-J. Hong, W. Stevenson, J. Ewing, J. Chacko, E. Rumi, A. Halpern, F. Palandri, N. Vianelli, F. Passamonti, R. Mesa, M. Marchetti, C. Harrison, A. Vannucchi, J. Watts, D. Ross, M. Talpaz, H. Rienhoff

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


Search Tools: